

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Herman Alan C.</u> (Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 201 REDWOOD SHORES PARKWAY, SUITE 200 (Street) REDWOOD CA 94065 CITY (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [CHRS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer
	3. Date of Earliest Transaction (Month/Day/Year) 11/12/2014	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.0001 par value	11/12/2014		X		239,952	A	\$1.667	239,952	D	
Common Stock, \$0.0001 par value	11/12/2014		J ⁽¹⁾		26,756	D	(1)	213,196	D	
Common Stock, \$0.0001 par value	11/12/2014		C		1,503	A	(2)	214,699	D	
Common Stock, \$0.0001 par value	11/12/2014		C		39,991	A	(2)	294,940 ⁽³⁾	I	By Trust ⁽⁴⁾
Common Stock, \$0.0001 par value	11/12/2014		C		5,224	A	(2)	300,164 ⁽³⁾	I	By Trust ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant to Purchase Common Stock	\$1.667	11/12/2014		X			239,952	(5)	(6)	Common Stock	239,952	\$0.00	0	D	
Warrant to Purchase Series B Preferred Stock	\$0.0167	11/12/2014		X			1,505	(5)	(6)	Series B Preferred Stock	1,505	\$0.00	0	D	
Series B Preferred Stock	(2)	11/12/2014		X		1,505		(2)	(7)	Common Stock	1,505	\$0.0167	1,505	D	
Series B Preferred Stock	(2)	11/12/2014		J ⁽⁸⁾			2	(2)	(7)	Common Stock	2	(2)	1,503	D	
Series B Preferred Stock	(2)	11/12/2014		C			1,503	(2)	(7)	Common Stock	1,503	(2)	0	D	
Series A Preferred Stock	(2)	11/12/2014		C			39,991	(2)	(7)	Common Stock	39,991	(2)	0	I	By Trust ⁽⁴⁾
Series B Preferred Stock	(2)	11/12/2014		C			5,224	(2)	(7)	Common Stock	5,224	(2)	0	I	By Trust ⁽⁴⁾

Explanation of Responses:

- Immediately prior to the closing of the IPO, the warrant automatically net exercised by its terms into Common Stock, which allowed the holder to pay the exercise price of the warrant by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.
- The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.
- A portion of these shares is subject to a right of repurchase held by the Issuer.
- These shares are held by the Herman Trust, dated March 16, 2001, of which Reporting Person is a co trustee.
- The warrant is immediately exercisable.
- The warrant expires upon the consummation of the Issuer's initial public offering to the extent not previously exercised.

7. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

8. Immediately prior to the closing of the IPO, the warrant automatically net exercised by its terms into Series B Preferred Stock, which allowed the holder to pay the exercise price of the warrant by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.

Remarks:

/s/ Matthew R. Hooper, as
Attorney-in-Fact for Alan C. 11/12/2014
Herman, Ph.D.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.